Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)
|
|
- Nicholas West
- 6 years ago
- Views:
Transcription
1 Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin Launch München, 19. Oktober 2017
2 FLT3 Mutations in AML FLT3 internal tandem duplications (ITD) found in ~25% of younger adult patients; associated with inferior prognosis High mutant-to-wild type ITD allelic ratio ( 0.5) ITD insertion site (JM vs. TK-1 domain) FLT3 tyrosin kinase domain (TKD) mutations in 8%; prognostic impact less well defined Impact for treatment: FLT3 inhibitors in clinical development 1 st generation: Midostaurin, lestaurtinib, sorafenib 2 nd generation: Quizartinib, crenolanib, gilteritinib Allogeneic hematopoietic cell transplantation improves outcome Litzow MR, Blood. 2005;106: Whitman SP et al. Absence of the WT allele predicts poor prognosis in adult de novo aml with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61(19):7233-9; Thiede C et al. Analysis of FLT3-activating mutations in 979 patients with AML association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12): ; Kottaridis PD et al. Activating ITD mutations of the fms-like tyrosine kinase-3 at complete response and relapse in patients with AML. Blood. 2002;100(7):2393-8; Gale R et al. The impact of FLT3 internal tandem duplication mutant level, number size and interaction with NPM1 mutations in a large cohort of young adult patients with AML. Blood. 2008;111(5): ; Breitenbuecher F et al. Identification of a novel type of ITD mutations in nonjkuxtamembran domains of the FLT3 tyrosine kinase receptor. Blood. 2009;113(17):4074-7; Kayser S et al. Insertion of FLT3 ITD in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12): ; Breitenbuecher F et al. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood. 2009;113(17): ; Schlenk RF et al. Differntial impact of allelic ration and insertion site in FLT3-ITD-positive AML with respecht to allegenic transplantation. Blood. 2014;124(23):3441-9; Stone RM et al. Midostaurin plus chemotherapy for AML with FLT3-Mutation. N Engl J Med. 2017;377:
3 Number of unique patients with driver mutation Genomic Landscape of Adult AML ELN risk category Favorable Intermediate I Intermediate II Adverse Not available Targeted resequencing of 111 myeloid cancer genes (combined with cytogenetic profiles) in 1540 AML 5236 driver mutations (i.e., fusion genes, copy number alterations, gene mutations) involving 77 loci 6 genes mutated in >10% pts; 13 genes 5-10% pts; 24 genes 2-5% pts; 37 genes <2% pts ELN: European Leukemia Net Papaemmanuil E et al. Genomic Classification and Prognosis in AML. N Engl J Med. 2016;374(23):
4 Driver Mutations with Effect on Overall Survival Adverse Favorable Papaemmanuil E et al. Genomic Classification and Prognosis in AML. N Engl J Med. 2016;374(23):
5 FLT3 Inhibitors in Clinical Development Relative selectivity and potency (IC 50 ) of TKIs against FLT3-ITD 1 st generation TKIs non-selective; unfavorable safety profile; when used as single agent, only transient blast reductions observed 2 nd generation TKIs (quizartinib [AC220], crenolanib, gilteritinib [ASP2215]) more selective and more potent TKI: Tyrosine Kinase Inhibitor, ITD: Internal Tandem Duplication Galanis A et al. Crenolanib: A next generation FLT3 inhibitor. Cancer Res. 2012;72:3660 (abstract); Karaman MW et al. A quantitativ analysis of kinase inhibitor selectivity. Nature Biotechnology. 2008;26(1): ; Zarrinkar PP et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of AML. Blood. 2009;114(14):
6 Midostaurin Preclinical Development Midostaurin (PKC412; N-benzoylstaurosporine) is a potent FLT3 (both ITD and TKD) inhibitor; also inhibits PKC, VEGFR, KIT, and PDGFR 1,2 Midostaurin specifically inhibits growth of leukemic cell lines made factor independent by transfection of activating FLT3 mutation (ITD or D835Y) 2 Midostaurin increased survival in a murine BMT model of FLT3-ITD myeloproliferative disorder 3 BMT: Bone Marrow Transplant; PKC: Protein Kinase C; VEGFR: Vascular Endothelial Growth Factor Receptor; PGFR: Platelet-derived Growth Factor Receptor; TKD = Tyrosine Kinase Domain 1 Propper DJ et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol. 2001;19: ; 2 Weisberg E et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1: Kelly LM et al. FLT3 ITD mutation associated with human acute myeloid leukemias induce myeloproliverative disease in a murine bone marrow transplant model. Blood. 2002;99:
7 Phase I/II Trials with PKC412 (Midostaurin) PKC412 (75mg TID) in 20 pts with r/r AML & FLT3 mutation 1 >50% reduction in BM blasts in 5/20 (25%), and PB blasts in 14/20 (70%) PKC412 (50/100 mg BID) in 92 pts with r/r AML 2 >50% reduction in BM or PB blasts: FLT3 mut : 25/35 (71%); FLT3 wt : 24/57 (42%) 3+7 induction + PKC412 (100/50 mg BID; continuous vs. intermittent dosing) in 69 pts with newly diagnosed AML 3 BM: Bone Marrow, PB: Peripheral Blood; PKC: Protein Kinase C 1 Stone R et al. Patients with AML and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54-60; 2 Fischer T et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase and multi-targeted kinase inhibitor, in patients with AML or high-risk MDS with either wild-type or mutated FLT3. J Clin Oncol. 2010;28: ; 3 Stone R et al. Phase IB Study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with AML. Leukemia. 2012;26:
8 Phase IB Trial Combining Intensive Chemotherapy with Midostaurin FLT3 mut : CR 12/13 (92%) FLT3 wt : CR 20/27 (74%) FLT3 mut FLT3 wt CR: Complete Remission Stone R et al. Phase IB Study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with AML. Leukemia. 2012;26:
9 Midostaurin in AML Stone RM et al. N Engl J Med. 2017;377:
10 Midostaurin in AML Basel, September 18, 2017 the European Commission (EC) approved midostaurin for two indications: Midostaurin is approved for use in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adults with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive It was also cleared for use as monotherapy for the treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) or mast cell leukemia The approval follows a positive opinion issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on July 20, 2017 and applies to all 28 EU member states, plus Iceland, Liechtenstein and Norway
11 Phase III Study of Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (RATIFY) CALGB, AMLSG, CETLAM, ECOG, EORTC, GIMEMA, NCIC, OSHO, PETHEMA, SAL, SWOG Induction (1-2 cycles) CR Consolidation** (up to 4 cycles) CR Postconsolidation (up to 12 cycles) Patients with newly diagnosed AML 18 to <60 years with activating FLT3 mutations Screening within 48hrs* Stratification by TKD and ITD (ratio <0.7 vs. 0.7) (n=717) R Double blind Midostaurin (50 mg bid, days 8-21) Daunorubicin (60 mg/m 2 /day, days 1-3) Cytarabine (200 mg/m 2 /day, days 1-7) Placebo (bid, days 8-21) Daunorubicin (60 mg/m 2 /day, days 1-3) Cytarabine (200 mg/m 2 /day, days 1-7) Midostaurin (50 mg bid, days 8-21) High-dose cytarabine (3 g/m 2 /day q12h, days 1, 3, and 5) Placebo (bid, days 8-21) High-dose cytarabine (3 g/m 2 /day q12h, days 1, 3, and 5) Midostaurin (50 mg bid, days 1-28) Placebo (bid, days 1-28) * Patients may receive hydroxyurea during screening phase ** Patients with an HLA-compatible family donor may proceed to allogeneic HSCT ClinicalTrials.gov NCT TKD: Tyrosine Kinase Domain, ITD: Internal Tandem Duplication, OS: Overall Survival, EFS: Event-Free Survival, HSCT: Hematopoietic Stem Cell Transplant Primary endpoint: OS Key secondary endpoint: EFS Stone RM et al. Midostaurin plus chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377:
12 Key Eligibility Criteria Age 18-60, normal end-organ function Documented AML (non-apl) De novo AML AML with antecedent history of MDS (but no therapy with HMA) Therapy-related AML excluded FLT3 mutation centrally determined prior to enrollment Assessed at one of 9 academic labs around the world Results within 48h Up to 5 days of hydroxyurea allowed prior to start of treatment while awaiting results of mutation analysis APL: Acute Promyelocytic Leukemia, MDS: Myelodysplastic Syndrome, HMA: Hypomethylating Agents
13 Design Considerations Primary endpoint: Overall survival, not censored for allogeneic transplantation Sample size: 714 evaluable patients HR = 0.78 for OS Power = 84% Type I error rate = (1-sided) Final analysis after 509 events (deaths) observed Interim analysis conducted at 50% of events HR: Hazard Ratio, OS: Overall Survival
14 Revised Analysis Plan Alliance DSMB and CTEP approved the primary analysis of OS to occur with a cut off of April 1, 2015 with 357 events Event rate reached a plateau: 6 events 2014, 3 in events predicted to occur in 2015 Higher than expected transplant rate: 25% in CR1, 57% overall Increased TKD mutation incidence: 23% Median follow-up time for survivors: 56.7 Months (range: 0.1, 79.2 Months) Critical value to declare statistical significance: (1-sided). DSMB: Data Safety Monitoring Board, CTEP: Cancer Therapy Evaluation Program (of the US National Cancer Institute), OS: Overall Survival, CR: Complete Remission, TKD: Tyrosine Kinase Domain
15 Consort Diagram Activated May 2008; completed accrual: Oct 2011 screened 3,277 patients Total FLT3 mut : n=896 (27% of screened) Total randomized: n=717 (80% of FLT3 mut ) Midostaurin n=360 Induction 1 n= received Induction completed Induction Consolidation n= completed Consolidation Maintenance n= completed Maintenance Placebo n=355 Induction 1 n= received Induction completed Induction Consolidation n= completed Consolidation Maintenance n=85 51 completed Maintenance
16 Patient Characteristics Median age (range), years (N = 717) 47.9 ( ) Midostaurin (n = 360) 47.1 ( ) Placebo (n = 357) P Value 48.6 ( ).22 Female sex, n (%) 398 (55.5) 186 (51.7) 212 (59.4).04 FLT3 stratification groups, n (%) 1.00 FLT3-TKD 162 (22.6) 81 (22.5) 81 (22.7) FLT3-ITD allelic ratio < (47.6) 171 (47.5) 170 (47.6) FLT3-ITD allelic ratio (29.8) 108 (30.0) 106 (29.7) Median WBC (range), 10 3 /μl ( ) ( ) ( ).72 Median platelet count (range), 10 3 /μl 50.0 ( ) 50.0 ( ) 50.0 ( ).58 Median ANC (range), per mm 2.2 (0-55.9) 2.2 (0-55.9) 2.3 ( ).65 TKD: Tyrosine Kinase Domain, ITD: Internal Tandem Domain; WBC: White Bloodcell Count, ANC: Absolute Neutrophile Cell Count Stone RM et al. Midostaurin plus chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377:
17 Patients Surviving, % Overall Survival (Primary Endpoint) Non-censored for Allogeneic HCT 22% reduced risk of death in the midostaurin arm (vs. placebo) Patients, n Midostaurin 360 Placebo yr OS: Midostaurin 51%; Placebo: 44% Median (95% CI), months HR (95% CI) P Value b 74.7 (31.5-NE) ( ).009 ( ) Patients at risk Time, months Midostaurin Placebo HCT: Hematopoietic Cell Transplant, HR: Hazard Ratio, CI: Confidence Interval, OS: Overall Survival Stone RM et al. Midostaurin plus chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377:
18 Consistent Effect on OS by FLT3 status (Secondary Endpoint) N HR (95% CI) HR (95% CI) P Value a Overall (stratified) ( ).009 FLT3-ITD high ( ).19 FLT3-ITD low ( ).19 FLT3-TKD ( ).10 0,25 0,5 0,75 1 1,25 Favors midostaurin Favors placebo a P value is one-sided for the overall (stratified) analysis; P values are two-sided for the analyses by FLT3 subgroup. FLT3-ITD-low, FLT3-ITD/-WT allelic ratio < 0.7; FLT3-ITD-high, FLT3-ITD/-WT allelic ratio 0.7. OS: Overall Survival, HR: Hazard Ratio, CI: Confidence Interval; TKD: Tyrosine Kinase Domain, ITD: Internal Tandem Domain Stone RM et al. Midostaurin plus chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377:
19 Consistent Effect on OS by FLT3 status (Secondary Endpoint) OS: Overall Survival; ITD: Internal Tandem Domain, TKD: Tyrosine Kinase Domain Stone RM et al. Midostaurin plus chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377:
20 Allogeneic Transplants by Arm By Arm MIDO N=360 PBO N=357 p-value CR1 only, n %: 95% CI (28%: 23, 33) (22%: 18, 26) 0.08 Type: Matched-related 47 (47%) 30 (38%) Type: Matched-unrelated 43 (43%) 42 (53%) Type: Other 10 (10%) 7 (9%) Transplant at any time, n %: 95% CI (59%: 54, 64) (55%: 50, 60) 0.28 Type: Matched-related 95 (45%) 69 (35%) Type: Matched-unrelated 89 (42%) 108 (56%) Type: Other 28 (13%) 18 (9%) 408 (57%) patients received a transplant MIDO: Midostaurin, PBO: Placebo, CR: Complete Remission, CI: Confidence Interval Stone RM et al. Midostaurin plus chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377:
21 Impact of Allogeneic HCT in CN-AML Molecular favorable genotypes NPM1 mut / FLT3-ITD neg Molecular unfavorable genotypes incl. FLT3-ITD+ and triple-neg. AML CN-AML: Cytogenetically Normal Acute Myeloid Leukemia, HCT: Hematopoetic Stem Cell Transplantation, ITD: Internal Tandem Duplication Schlenk RF et al. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. N Engl J Med. 2008;358(18):
22 Patients Surviving, % SCT in CR Patients at risk SCT outside CR1 Overall Survival (OS) Post-Transplant Treatment with Midostaurin increases OS after HCT in CR1 SCT in CR1 SCT outside CR1 Patients, n Median (95% CI), months Midostaurin 101 NE (69.8-NE) Placebo 81 NE (21.8-NE) Midostaurin ( ) Placebo ( ) Time, months Midostaurin 101 Placebo 81 Midostaurin 112 Placebo a Stratified on FLT3 subtype; 2-sided, log-rank P value. OS: Overall Survival, HCT: Hematopoetic Stem Cell Transplantation, CR: Complete Remission; SCT: Stem Cell Transplantation; NE: Not Reached P Value a Stone RM et al. Midostaurin plus chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377:
23 Patients, % Most Common Non-Hematologic Grade 3 Events Reported During Treatment 100 Top 20 non-hematologic AEs regardless of attribution 80 P =.84 Midostaurin (n = 355) Placebo (n = 354) 60 P = P =.35 P =.92 P =.25 P =.82 P =.19 P =.008 P =.53 P =.89 P =.05 P =.32 P =.67 P =.38 P =.14 P =.76 0 a Infection includes the following terms: infection with grade 3/4 neutrophils (ANC < /μl), infections with normal ANC or grade 1/2 neutrophils, infection with unknown ANC, opportunistic infection associated with grade 2 lymphopenia, and other infections. b Fatigue includes asthenia, lethargy, and malaise. c Includes pneumonitis and pulmonary infiltrates. AEs: Adverse Events Stone RM et al. Midostaurin plus chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377:
24 Patients, % Grade 3 Hematologic Events AEs occurring in 20% of patients regardless of attribution 100 P =.52 P =.86 P = Midostaurin (n = 355) Placebo (n = 354) P =.32 P =.35 0 Thrombocytopenia Neutropenia Anemia Leukopenia Lymphocytopenia AEs: Adverse Events Stone RM et al. Midostaurin plus chemotherapy for Acute Myeloid Leukemia with FLT3 Mutation. N Engl J Med. 2017;377:
25 Conclusions Midostaurin, a multi-targeted kinase inhibitor, improves overall survival and event-free survival when added to standard chemotherapy with one-year maintenance in patients aged with newly diagnosed ITD and TKD FLT3- mutant AML (RATIFY trial) Results from the AMLSG trial (NCT ) suggest that midostaurin may also improve outcome in patients aged No increase in non-hematologic and hematologic toxicity Midostaurin in combination with standard chemotherapy is the first targeted therapy of AML and will represent the new standard in adult patients with newly diagnosed AML and activating FLT3 mutations An international academic-industry collaborative AML study based on genotype at diagnosis is feasible AML: Acute Myeloid Leukemia, ITD: Internal Tandem Domain, TKD: Tyrosine Kinase Domain
26 Vielen Dank
Molecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationAcute Myeloid Leukemia: State of the Art in 2018
Acute Myeloid Leukemia: State of the Art in 2018 Harry P. Erba, MD, PhD Professor, Department of Medicine Director, Leukemia Program Duke University Durham, NC Treatment Paradigm of Adults with AML Fit
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationBest of ASH: Acute leukemia. Frédéric Baron
Best of ASH: Acute leukemia Frédéric Baron I Acute Myeloid Leukemia Flt3 inhibitors (ratify, sorafenib after HCT) 5 other important abstracts (in brief) Mutated genes in AML FLT3: The Cancer Genome Atlas
More informationGENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA
CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationNovel Induction and Targeted Strategies in Acute Myeloid Leukemia
Novel Induction and Targeted Strategies in Acute Myeloid Leukemia Eytan M. Stein, MD Leukemia Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Current Paradigms
More informationMidostaurin bei FLT3-mutierter AML: Praxisnutzen der ersten zielgerichteten Therapieoption
bei FLT3-mutierter AML: Praxisnutzen der ersten zielgerichteten Therapieoption PD Dr. med. Thomas Schroeder Klinik für Hämatologie, Onkologie und Klinische Immunologie Wien, 29.09.2018 Grimwade et al.,
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationmidostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age.
midostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age. perc deliberated on the toxicity profile of midostaurin and noted that
More informationPage: 1 of 12. Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Leukemia
Page: 1 of 12 Last Review Status/Date: September 2015 Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Description Treatment of acute myeloid leukemia (AML) is based upon risk stratification,
More informationFLT3 inhibitors in AML
FLT3 inhibitors in AML Richard M Stone, MD Director, Adult Leukemia Program Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School Disclosures- Richard M. Stone, MD Consulting relationships:
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More information2/10/2017. Updates in Acute Leukemia Therapy Blood Cancer Incidence in the United States, Leukemia Incidence in the Unites States, 2016
Updates in Acute Leukemia Therapy 2017 Aaron Logan, MD, PhD UCSF Division of Malignant Hematology and Blood and Marrow Transplantation aaron.logan@ucsf.edu @hemedoc Blood Cancer Incidence in the United
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationMidostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
The new england journal of medicine Original Article Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation R.M. Stone, S.J. Mandrekar, B.L. Sanford, K. Laumann, S. Geyer, C.D. Bloomfield,
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationSUPPLEMENTARY FIG. S3. Kaplan Meier survival analysis followed with log-rank test of de novo acute myeloid leukemia patients selected by age <60, IA
Supplementary Data Supplementary Appendix A: Treatment Protocols Treatment protocols of 123 cases patients were treated with the protocols as follows: 110 patients received standard DA (daunorubicin 45
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationGenetic Testing for FLT3 and NPM1, and CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia
Genetic Testing for FLT3 and NPM1, and CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia Policy Number: 2.04.124 Last Review: 09/2017 Origination: 9/2014 Next Review: 09/2018 Policy Blue
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationFLT-3 inhibitors in AML
FLT-3 inhibitors in AML Jorge Sierra Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona Rome, September 24, 2017 Disclosures Advisory board: Pfizer, NovarHs, Jazz, Celgene, SeaIle
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationDaunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Find Studies About Studies Submit Studies Resources About Site Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia The safety and scientific validity
More informationWe updated the design of this site on December 18, Previous Study Return to List Next Study
We updated the design of this site on December 18, 2017. Learn more. Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: AC220-A-U302 Previous Study Return to List Next
More informationAcute myeloid leukemia: a comprehensive review and 2016 update
OPEN Citation: (2016) 6, e441; doi:10.1038/bcj.2016.50 www.nature.com/bcj REVIEW Acute myeloid leukemia: a comprehensive review and 2016 update I De Kouchkovsky 1 and M Abdul-Hay 1,2 Acute myeloid leukemia
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationOUTCOME OF ACUTE MYELOID LEUKEMIA IN PATIENTS UP TO 65 YEARS OF AGE AT HEMATOLOGY AND BONE MARROW TRANSPLANTATION UNIT IN ALGIERS DURING 14 YEARS
OUTCOME OF ACUTE MYELOID LEUKEMIA IN PATIENTS UP TO 65 YEARS OF AGE AT HEMATOLOGY AND BONE MARROW TRANSPLANTATION UNIT IN ALGIERS DURING 14 YEARS S.Akhrouf, F.Belhadri, A.Talbi, H.Moussaoui, M.Benakli,
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationBC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib
BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid
More informationGenetic Testing for FLT3 and NPM1, and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia
Genetic Testing for FLT3 and NPM1, and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia Policy Number: 2.04.124 Last Review: 09/2018 Origination: 9/2014 Next Review: 09/2019 Policy Blue
More informationAML Emerging Treatment Strategies
Welcome and Introduction Clare Karten, MS Senior Director, Mission Education The Leukemia & Lymphoma Society AML Emerging Treatment Strategies Wendy Stock, MD Professor of Medicine, Section of Hematology/Oncology
More informationCharacteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies
Characteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies Sabine Kayser, * Julia Krzykalla, Michelle A. Elliott, Kelly Norsworthy, Patrick Gonzales,
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationTREATMENT UPDATES IN ACUTE LEUKEMIA. Shannon McCurdy, MD University of Pennsylvania
TREATMENT UPDATES IN ACUTE LEUKEMIA Shannon McCurdy, MD University of Pennsylvania TIMELINE FOR FDA APPROVED AGENTS FOR AML Midostuarin Enasidenib Cytarabine + Daunorubicin (7+3) Gemtuzumab Ozogamicin
More informationCautionary Note Regarding Forward-Looking Statements
lndoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1
More informationScottish Medicines Consortium
Scottish Medicines Consortium azacitidine 100mg powder for suspension for injection (Vidaza ) No. (589/09) Celgene Ltd 05 March 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationRydapt. Summary of the Risk Management Plan (RMP) for Rydapt (midostaurin)
Regulatory Affairs Rydapt 25 mg soft capsules Summary of the Risk Management Plan (RMP) for Rydapt (midostaurin) Document version: 01 Document status: Document Date: Final 02-June-2017 1 of 6 Summary of
More informationNUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia
Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationMinimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationMyeloperoxidase Expression in Acute Myeloid Leukemia Helps Identifying Patients to Benefit from Transplant
Original Article http://dx.doi.org/1349/ymj.212.53.3.53 pissn: 513-5796, eissn: 1976-2437 Yonsei Med J 53(3):53-536, 212 Myeloperoxidase Expression in Acute Myeloid Leukemia Helps Identifying Patients
More informationCARE at ASH 2014 Leukemia. Julie Bergeron, MD Maisonneuve-Rosemont Hospital
CARE at ASH 2014 Leukemia Julie Bergeron, MD Maisonneuve-Rosemont Hospital Acute Leukemias Dr. Julie Bergeron Hôpital Maisonneuve-Rosemont, Montréal Disclosures Advisory boards in 2014: AMGEN EUSA pharma
More informationAcute Leukemia. Sebastian Giebel. Geneva 03/04/
Acute Leukemia (including ALL) Sebastian Giebel Geneva 03/04/2012 www.ebmt.org Acute leukemias: EBMT survey 2 AML: EBMT survey Gratwohl A, et al. Bone Marrow Transplant 2009 3 Acute leukemias: INCIDENCE
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationASCO 2009 Leukemia MDS -Transplant
ASCO 2009 Leukemia MDS -Transplant Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Scottsdale, AZ, USA mesa.ruben@mayo.edu American Society of Hematology State-of-the-Art Symposium
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationMidostaurin with standard chemotherapy in FLT3-positive acute myeloid leukemia
Midostaurin with standard chemotherapy in FLT3-positive acute myeloid leukemia EUnetHTA report DSD: Horizon Scanning in Oncology No.74 EUnetHTA Joint Action 3 WP4 Rapid assessment of pharmaceutical technologies
More informationCytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
Acute Myeloid Leukemia Articles Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Bruno C. Medeiros, 1 Megan Othus, 2,3 Min Fang, 3,4 Frederick R. Appelbaum,
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: 5.21.93 Rydapt (midostaurin) Genetic Testing for FLT3, NPM1, and CEBPA Variants in Description Treatment of acute myeloid leukemia
More informationUpdates in Treatment Strategies for Acute Leukemia. Alexander Perl, MD Assistant Professor, Hematology/Oncology University of Pennsylvania 1/22/2016
Updates in Treatment Strategies for Acute Leukemia Alexander Perl, MD Assistant Professor, Hematology/Oncology University of Pennsylvania 1/22/2016 What is happening to standard of care in 2017? AML treatment
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationGilteritinib for relapsed or refractory acute myeloid
NIHR Innovation Observatory Evidence Briefing: May 2018 Gilteritinib for relapsed or refractory acute myeloid leukaemia (AML) with an FLT3 mutation second line NIHRIO (HSRIC) ID: 11486 NICE ID: 8749 LAY
More informationLong-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single
More informationGenetic Testing for FLT3, NPM1, and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia
Genetic Testing for FLT3, NPM1, and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationAdvances in the Management of Acute Leukemia
Advances in the Management of Acute Leukemia Tara L. Lin, MD Director, Acute Leukemia Program Conflict of Interest I have no conflicts to disclose 2 1 ALL Newly diagnosed SCT in CR1 Options in the R/R
More informationMedical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Medical Policy MP 8.01.26 BCBSA Ref. Policy: 8.01.26 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy Related Policies 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in
More information7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, Eva Lengfelder
Frontline therapy of acute promyelocytic leukemia: randomized comparison of ATRA and intensified chemotherapy including high dose cytosine-arabinoside versus ATRA and anthracyclines - A prospective multicenter
More informationTools for MRD in AML: flow cytometry
ACUTE MYELOID LEUKEMIA MEETING Ravenna - October 27, 2017 Tools for MRD in AML: flow cytometry Francesco Buccisano Can MRD improve outcome determina3on? No. of leukemic cells 10 12 10 10 10 8 10 6 10 4
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationClassical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis. Francesco Passamonti Università degli Studi dell Insubria, Varese
Classical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis Francesco Passamonti Università degli Studi dell Insubria, Varese DIPSS during f-up IPSS at diagnosis Diagnose MF and genotype
More informationLearning Objectives. Case A: Presentation. Case A Question Not included in Activity Survey. Acute Leukemia: Diagnosis and Prognosis
Learning Objectives Improve awareness of FDA-approved agents and/or therapies under development for the treatment of AML and ALL Incorporate FDA-approved agents and therapies under development into treatment
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More information2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA
2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA Adriano Venditti Ematologia Universita Tor Vergata, Roma Current Treatment Results in AML AGE, y CR%
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Gemtuzumab ozogamacin for untreated de novo acute myeloid leukaemia Response to consultee and commentator comments re-scope Please note: Comments received in the course
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationBlast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome
RESEARCH ARTICLE Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome AJH Mrinal M. Patnaik, 1 Emnet A. Wassie, 1 Terra L. Lasho, 2 Curtis
More informationIDH1 AND IDH2 MUTATIONS
Mutant Isocitrate Dehydrogenase (midh) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationEHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication)
EHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication) ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS):
More informationKeywords: Acute Myeloid Leukemia, FLT3-ITD Mutation, FAB Subgroups, Cytogenetic Risk Groups
Original Articleeee fms Like Tyrosine kinase3- Internal Tandem Duplication (FLT3-ITD) in Acute Myeloid Leukemia, Mutation Frequency and its Relation with Complete Remission, 2007-2008 Emami AH, 1 Shekarriz
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More information